Advertisement

Journal of Endocrinological Investigation

, Volume 21, Issue 4, pp 257–262 | Cite as

Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration

  • Annamaria Colao
  • R. Pivonello
  • D. Ferone
  • G. La Tessa
  • A. Faggiano
  • G. Facciolli
  • C. Di Somma
  • B. Merola
  • G. Lombardi
Article

Abstract

Atrial natriuretic factor (ANF) was suggested to be involved as neurohormone in the modulation of hypothalamus-pituitary-adrenal axis in humans. However, this role is still controversial and widely discussed. In order to evaluate whether ANF is secreted in the hypothalamus-pituitary system in humans, plasma ANF concentrations were assayed in samples collected in the inferior petrosal sinus (IPS) blood of patients subjected to IPS sampling for diagnostic purposes or neurosurgical indications. In this retrospective study were included 22 patients: 10 with Cushing’s disease (CD) and 12 patients with GH or PRL-secreting pituitary adenoma, used as control group. In the patients with CD, plasma ANF concentration was also assayed after CRH test (hCRH 100 µg as iv bolus with blood samples after 5, 10 and 15 min). Both in patients with CD and in patients with GH- or PRL-secreting pituitary adenoma, no significant difference was found in plasma ANF levels between IPS ipsilateral (13.0±1.5 and 12.2±1.2 pmol/l) or contralateral (13.0±1.6 and 12.2±1.4 pmol/l) to the adenoma and peripheral blood (14.2±2.0 and 13.7±1.5 pmol/l, respectively). Similarly, no difference was found between the IPS ipsilateral and contralateral to the adenoma in both groups of patients. In patients with CD, CRH administration induced a significant increase of ACTH levels (periphery: 34.9±6.2 vs 11.5±2.3 pmol/l, p<0.05) but it did not induce any significant change of plasma ANF levels (14.0±2.0 vs 13.4±1.4 pmol/l in the ipsilateral IPS and 13.4±1.6 vs 13.4±1.5 pmol/l in the contralateral IPS). In conclusion, the lack of ANF concentration gradient between IPS and peripheral blood, the lack of any difference in ANF concentrations between patients with CD and acromegalics or hyperprolactinemics and the absence of ANF response to CRH administration do not support the hypothesis of a role for ANF as neurohormone involved in the hypothalamus-pituitary control and particularly in the hypothalamus-pituitary-adrenal axis modulation in humans.

Key-words

Cushing’s disease atrial natriuretic hormone corticotropin-releasing hormone inferior petrosal sinus sampling pituitary diseases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeBold AJ. Atrial natriuretic factor: an overview. Fed. Proc. 45: 2081, 1986.Google Scholar
  2. 2.
    Gutkowska J., Autunes-Rodrigues J., McCann S.M. Atrial natriuretic peptide in brain and pituitary gland. Physiol. Rev. 77: 465, 1997.PubMedGoogle Scholar
  3. 3.
    King M.S., Baertschi A.J. Physiological concentrations of atrial natriuretic factor with intact N-terminal sequences inhibit corticotropin-releasing factor-stimulated adrenocorticotropin secretion from cultured anterior pituitary cells. Endocrinology 124: 286, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Kovacs K.J., Antoni F.A. Atriopeptin inhibits stimulated secretion of adrenocorticotropin in rats: evidence for pituitary site of action. Endocrinology 127: 3003, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Antoni F.A., Hunter E.F.M., Lowry P.J., Noble J.M., Seçkl J.R. Atriopeptin: an endogenous corticotropin-release inhibiting hormone. Endocrinology 130: 1753, 1992.PubMedGoogle Scholar
  6. 6.
    Kellner M., Wiedemann K., Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and Cortisol in man. Life Sci. 50: 1835, 1992.PubMedCrossRefGoogle Scholar
  7. 7.
    Ur E., Faria M., Tsagarakis S., Anderson J.V., Besser G.M., Grossman A. Atrial natriuretic peptide in physiological doses does not inhibit the ACTH or Cortisol response to corticotropin-releasing hormone-41 in normal human subjects. J. Endocrinol. 131: 163, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Wittert G.A., Espiner E.A., Richards A.M., Donald R.A., Livesey J.H., Yandle T.G. Atrial natriuretic factor reduces vasopressin and angiotensin II but not the ACTH response to acute hypoglycaemic stress in normal men. Clin. Endocrinol. (Oxf.) 38: 183, 1993.CrossRefGoogle Scholar
  9. 9.
    Ambrosi B., Sala C., Bochicchio D., Colombo P., Gazzano G., Fadin C., Morganti A., Faglia G. Effect of atrial natriuretic factor infusion on basal and CRH-stimulated ACTH, Cortisol and aldosterone levels in patients with Cushing’s or Addison’s disease. Clin. Endocrinol. (Oxf.) 40: 589, 1994.CrossRefGoogle Scholar
  10. 10.
    Gerbes A.L., Daghino L., Nguyen T., Nemer M. Transcription of brain natriuretic peptide and atrial natriuretric peptide genes in human tissues. J. Clin. Endocrinol. Metab. 78: 1307, 1994.PubMedGoogle Scholar
  11. 11.
    Snyman C., Naidoo Y., Narotam P.K., Figueroa C.D., Van Dellen J.R., Bhoola K.D. Cellular localization of atrial natriuretic peptide and tissue kallicrein in the human hypothalamus. Braz. J. Med. Biol. Res. 27: 1877, 1994.PubMedGoogle Scholar
  12. 12.
    Oldfield E.H., Doppman J.L., Nieman L.K., Chrousos G.P., Miller D.L., Kats D.A., Cutler G.B., Loriaux D.L. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N. Engl. J. Med. 325: 897, 1991.PubMedCrossRefGoogle Scholar
  13. 13.
    Lombardi G., Merola B., Miletto P., Colao A., De Chiara G., Iaccarino V., Spaziante R., Di Renzo G.F., Taglialatela M., Annunziato L. Plasma prolactin levels in inferior petrosal sinuses in various pituitary disorders during perihypophysial phlebography. Neuroendocrinology 46: 333, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Merola B., Colao A., Rossi E., La Tessa G., Spaziante R., Lombardi G. Hormonal gradients between inferior petrosal sinuses in various pituitary diseases. Acta Endocrinol. (Copenh.) 126: 419, 1992.Google Scholar
  15. 15.
    Colao A., Merola B., Boudouresque F., La Tessa G., Oliver C., Lombardi G. ACTH and p-endorphin concentrations in the inferior petrosal sinuses in various pituitary diseases. J. Endocrinol. Invest. 55: 807, 1992.Google Scholar
  16. 16.
    Colao A., Merola B., Cataldi M., La Tessa G., Boudouresque F., Oliver C., Di Renzo G.F., Annunziato L., Lombardi G. Alpha-melanocyte stimulating hormone is present in the inferior petrosal sinuses in patients with Cushing’s disease. Neuroendocrinology 358: 227, 1993.CrossRefGoogle Scholar
  17. 17.
    Colao A., Ferone D., Di Sarno A., Tripodi F.S., Cerbone G., Marzullo P., Boudouresque F., Oliver C., Merola B., Lombardi G. Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. Clin. Endocrinol. (Oxf.) 45: 157, 1996.CrossRefGoogle Scholar
  18. 18.
    Merola B., Longobardi S., Colao A., Di Somma C., Ferone D., Di Relia F., Pivonello R., Covelli V., Annunziato A., Lombardi G. Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing’s disease. In vivo and in vitro studies. Neuroendocrinology 64; 393, 1996.PubMedCrossRefGoogle Scholar
  19. 19.
    Ibanez-Santos J., Tsagarakis S., Rees L.H., Besser G.M., Grossman A. Atrial natriuretic peptides inhibit the release of corticotrophin-releasing factor-41 from rat hypothalamus in vitro. J. Endocrinol. 126: 223, 1990.PubMedCrossRefGoogle Scholar
  20. 20.
    Clerico A., Del Chicca M.G., Giganti M., Zucchelli G.C., Piffanelli A. Evaluation and comparison of the analytical performances of two RIA kits for the assay of atrial natriuretic peptides (ANP). J. Nucl. Med. Allied. Sci. 34: 81, 1990PubMedGoogle Scholar
  21. 21.
    Clerico A., Iervasi G., Del Chicca M.G., Maffei S., Berti S., Sabatino L., Turchi S., Cazzuola F., Manfredi C., Biagini A. Analytical performance and clinical usefulness of a commercially available IRMA kit for measuring atrial natriuretic peptide in patients with heart failure. Clin. Chem. 42: 1627, 1996.PubMedGoogle Scholar
  22. 22.
    Aburaya M., Minamino N., Hino J., Kangawa K., Matsuo H. Distribution and molecular forms of brain natriuretic peptide in the central nervous system, heart and peripheral tissue of rat. Biochem. Biophys. Res. Commun. 165: 880, 1989.PubMedCrossRefGoogle Scholar
  23. 23.
    Ueda S., Minamino N., Aburaya M., Kangawa K., Matsukura S., Matsuo H. Distribution and characterization of immunoreactive porcine C-type natriuretic peptide. Biochem. Biophys. Res. Commun. 175: 759, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1998

Authors and Affiliations

  • Annamaria Colao
    • 2
  • R. Pivonello
    • 2
  • D. Ferone
    • 2
  • G. La Tessa
    • 1
  • A. Faggiano
    • 2
  • G. Facciolli
    • 2
  • C. Di Somma
    • 2
  • B. Merola
    • 2
  • G. Lombardi
    • 2
  1. 1.Istituto di RadiologiaUniversità “Federico II”NapoliItaly
  2. 2.Department of Molecular and Clinical Endocrinology and Oncology“Federico II” UniversityNaplesItaly

Personalised recommendations